vs
Apellis Pharmaceuticals, Inc.（APLS）与EverCommerce Inc.（EVCM）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是EverCommerce Inc.的1.3倍（$199.9M vs $151.2M），EverCommerce Inc.净利率更高（4.0% vs -29.5%，领先33.5%），EverCommerce Inc.同比增速更快（5.2% vs -5.9%），EverCommerce Inc.自由现金流更多（$21.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 4.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
EverCommerce Inc.是面向服务类中小企业的领先集成SaaS解决方案提供商，核心市场覆盖北美及部分全球区域，产品线包含业务管理、支付处理、客户互动、营销工具等，服务家庭服务、健康康养、健身等多个细分领域。
APLS vs EVCM — 直观对比
营收规模更大
APLS
是对方的1.3倍
$151.2M
营收增速更快
EVCM
高出11.1%
-5.9%
净利率更高
EVCM
高出33.5%
-29.5%
自由现金流更多
EVCM
多$35.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $151.2M |
| 净利润 | $-59.0M | $6.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 8.8% |
| 净利率 | -29.5% | 4.0% |
| 营收同比 | -5.9% | 5.2% |
| 净利润同比 | -62.2% | 149.4% |
| 每股收益（稀释后） | $-0.40 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEVCM
| Q4 25 | $199.9M | $151.2M | ||
| Q3 25 | $458.6M | $147.5M | ||
| Q2 25 | $178.5M | $148.0M | ||
| Q1 25 | $166.8M | $142.3M | ||
| Q4 24 | $212.5M | $143.7M | ||
| Q3 24 | $196.8M | $140.1M | ||
| Q2 24 | $199.7M | $140.5M | ||
| Q1 24 | $172.3M | $137.9M |
净利润APLSEVCM
| Q4 25 | $-59.0M | $6.0M | ||
| Q3 25 | $215.7M | $11.1M | ||
| Q2 25 | $-42.2M | $8.2M | ||
| Q1 25 | $-92.2M | $-7.7M | ||
| Q4 24 | $-36.4M | $-12.2M | ||
| Q3 24 | $-57.4M | $-9.2M | ||
| Q2 24 | $-37.7M | $-3.4M | ||
| Q1 24 | $-66.4M | $-16.3M |
营业利润率APLSEVCM
| Q4 25 | -25.6% | 8.8% | ||
| Q3 25 | 48.7% | 10.8% | ||
| Q2 25 | -18.6% | 10.7% | ||
| Q1 25 | -50.0% | 10.0% | ||
| Q4 24 | -12.3% | 8.8% | ||
| Q3 24 | -24.0% | 7.2% | ||
| Q2 24 | -14.7% | 5.5% | ||
| Q1 24 | -36.0% | -3.1% |
净利率APLSEVCM
| Q4 25 | -29.5% | 4.0% | ||
| Q3 25 | 47.0% | 7.5% | ||
| Q2 25 | -23.6% | 5.5% | ||
| Q1 25 | -55.3% | -5.4% | ||
| Q4 24 | -17.1% | -8.5% | ||
| Q3 24 | -29.2% | -6.5% | ||
| Q2 24 | -18.9% | -2.4% | ||
| Q1 24 | -38.5% | -11.8% |
每股收益（稀释后）APLSEVCM
| Q4 25 | $-0.40 | $0.04 | ||
| Q3 25 | $1.67 | $0.06 | ||
| Q2 25 | $-0.33 | $0.04 | ||
| Q1 25 | $-0.74 | $-0.04 | ||
| Q4 24 | $-0.30 | $-0.06 | ||
| Q3 24 | $-0.46 | $-0.05 | ||
| Q2 24 | $-0.30 | $-0.02 | ||
| Q1 24 | $-0.54 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $129.7M |
| 总债务越低越好 | — | $523.4M |
| 股东权益账面价值 | $370.1M | $716.9M |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.73× |
8季度趋势，按日历期对齐
现金及短期投资APLSEVCM
| Q4 25 | $466.2M | $129.7M | ||
| Q3 25 | $479.2M | $106.9M | ||
| Q2 25 | $370.0M | $151.1M | ||
| Q1 25 | $358.4M | $148.4M | ||
| Q4 24 | $411.3M | $135.8M | ||
| Q3 24 | $396.9M | $101.6M | ||
| Q2 24 | $360.1M | $86.7M | ||
| Q1 24 | $325.9M | $90.0M |
总债务APLSEVCM
| Q4 25 | — | $523.4M | ||
| Q3 25 | — | $524.6M | ||
| Q2 25 | — | $525.8M | ||
| Q1 25 | — | $526.9M | ||
| Q4 24 | — | $527.9M | ||
| Q3 24 | — | $529.0M | ||
| Q2 24 | — | $530.1M | ||
| Q1 24 | $93.1M | $531.1M |
股东权益APLSEVCM
| Q4 25 | $370.1M | $716.9M | ||
| Q3 25 | $401.2M | $728.5M | ||
| Q2 25 | $156.3M | $744.0M | ||
| Q1 25 | $164.2M | $739.6M | ||
| Q4 24 | $228.5M | $750.8M | ||
| Q3 24 | $237.1M | $770.7M | ||
| Q2 24 | $264.3M | $784.1M | ||
| Q1 24 | $266.7M | $800.7M |
总资产APLSEVCM
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $821.4M | $1.4B | ||
| Q1 25 | $807.3M | $1.4B | ||
| Q4 24 | $885.1M | $1.4B | ||
| Q3 24 | $901.9M | $1.5B | ||
| Q2 24 | $904.5M | $1.5B | ||
| Q1 24 | $831.9M | $1.5B |
负债/权益比APLSEVCM
| Q4 25 | — | 0.73× | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | 0.71× | ||
| Q4 24 | — | 0.70× | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | 0.35× | 0.66× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $21.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $21.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 13.9% |
| 资本支出强度资本支出/营收 | 0.1% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 3.52× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $109.2M |
8季度趋势，按日历期对齐
经营现金流APLSEVCM
| Q4 25 | $-14.2M | $21.3M | ||
| Q3 25 | $108.5M | $32.5M | ||
| Q2 25 | $4.4M | $27.0M | ||
| Q1 25 | $-53.4M | $30.7M | ||
| Q4 24 | $19.4M | $48.4M | ||
| Q3 24 | $34.1M | $27.5M | ||
| Q2 24 | $-8.3M | $23.9M | ||
| Q1 24 | $-133.0M | $13.3M |
自由现金流APLSEVCM
| Q4 25 | $-14.3M | $21.0M | ||
| Q3 25 | $108.3M | $31.6M | ||
| Q2 25 | $4.4M | $26.5M | ||
| Q1 25 | $-53.4M | $30.2M | ||
| Q4 24 | $19.3M | $48.2M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | $-8.4M | $23.3M | ||
| Q1 24 | $-133.3M | $12.9M |
自由现金流率APLSEVCM
| Q4 25 | -7.1% | 13.9% | ||
| Q3 25 | 23.6% | 21.4% | ||
| Q2 25 | 2.5% | 17.9% | ||
| Q1 25 | -32.0% | 21.2% | ||
| Q4 24 | 9.1% | 33.5% | ||
| Q3 24 | — | 19.5% | ||
| Q2 24 | -4.2% | 16.6% | ||
| Q1 24 | -77.3% | 9.4% |
资本支出强度APLSEVCM
| Q4 25 | 0.1% | 0.2% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.2% | 0.3% |
现金转化率APLSEVCM
| Q4 25 | — | 3.52× | ||
| Q3 25 | 0.50× | 2.93× | ||
| Q2 25 | — | 3.31× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EVCM
| Transferred Over Time | $146.4M | 97% |
| Transferred At Point In Time | $4.8M | 3% |
